沙立度胺联合VAD方案治疗多发性骨髓瘤22例疗效观察  

Clinical efficacy of thalidomide combined VAD regimen in the treatmen of 22 cases multiple myeloma

作　　者：杨晓煜[1] 王琰[1] 

机构地区：[1]河南省郑州大学第五附属医院血液科,450052

出　　处：《中国实用医药》2010年第5期37-38,共2页China Practical Medicine

摘　　要：目的观察采用沙立度胺联合VAD方案治疗初发多发性骨髓瘤(MM)患者的临床疗效。方法对22例初发MM患者采用沙立度胺联合VAD方案化疗,每21d为1个疗程,1个疗程后间歇4周,观察疗效及药物毒副反应。结果治疗3个疗程后,22例患者部分缓解27.2%(6/22)、进步54.5%(12/22)、总有效率为81.8%(18/22)。毒副反应为骨髓抑制,指端麻木及便秘等。结论沙立度胺联合VAD方案治疗初发MM患者疗效较好,值得临床推广。Objective To observe the clinical curative effect of thalidomide combined VAD regimen on treating newly diagnosed multiple myeloma（MM）patiens. Methods Of 22 patients with newly diagnosed MM treated with thalidomide combined VAD regimen. Every 21 days a course of treatment, An intermittent 4 weeks after treatment, Observation of efficacy and toxicity of drugs. Results After treatment for 3 treatments, Among the 22 patients 6 achieved partial remission （ 27. 2% ）, 12 improved （ 54. 5% ） and the total effective rate 81.8%. Drug toxicity were bone marrow suppression, fingertip numbness and constipation etc. Conclusion Treating newly diagnosed multiple myeloma（MM） patiens with thalidomide combined VAD regimen can obtain a better efficacy, which is worth to practice in clinics.

关 键 词：沙立度胺 VAD方案 多发性骨髓瘤 

分 类 号：R733.3[医药卫生—肿瘤]